Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tomer M Mark

Showing results (31-40 of 46) with videos related to

Pageof 5
Sort By:
Cancer|November 6, 2018
Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myelomaAjai Chari, Sagar Lonial, Tomer M Mark, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 28, 2020
Exploiting Protein Translation Dependence in Multiple Myeloma with Omacetaxine-Based TherapyZachary J Walker, Beau M Idler, Lorraine N Davis, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 13, 2017
A Phase I Trial of High-Dose Lenalidomide and Melphalan as Conditioning for Autologous Stem Cell Transplantation in Relapsed or Refractory Multiple MyelomaTomer M Mark, Danielle Guarneri, Peter Forsberg, et al.
Blood Advances|August 30, 2023
CD38 antibody re-treatment in daratumumab-refractory multiple myeloma after time on other therapiesOlivia Perez de Acha, Lauren Reiman, David S Jayabalan, et al.
American Journal of Hematology|August 23, 2021
Carfilzomib and dexamethasone induction with lenalidomide, clarithromycin and dexamethasone consolidation and lenalidomide maintenance for newly diagnosed multiple myelomaPeter A Forsberg, Adriana C Rossi, Angelique Boyer, et al.
British Journal of Haematology|February 8, 2021
Health-related quality of life maintained over time in patients with relapsed or refractory multiple myeloma treated with daratumumab in combination with bortezomib and dexamethasone: results from the phase III CASTOR trialVania Hungria, Meral Beksac, Katja C Weisel, et al.
American Journal of Hematology|February 12, 2019
Phase II study of carfilzomib and dexamethasone therapy for newly diagnosed multiple myelomaPeter A Forsberg, Adriana C Rossi, Angelique Boyer, et al.
Bone Marrow Transplantation|June 14, 2019
High-dose bendamustine and melphalan conditioning for autologous stem cell transplantation for patients with multiple myelomaAlexandra Gomez-Arteaga, Tomer M Mark, Danielle Guarneri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 30, 2013
Overcoming the response plateau in multiple myeloma: a novel bortezomib-based strategy for secondary induction and high-yield CD34+ stem cell mobilizationRuben Niesvizky, Tomer M Mark, Maureen Ward, et al.
The New England Journal of Medicine|August 25, 2016
Daratumumab, Bortezomib, and Dexamethasone for Multiple MyelomaAntonio Palumbo, Asher Chanan-Khan, Katja Weisel, et al.
Pageof 5

Showing results (31-40 of 46) with videos related to

Sort By:
Pageof 5
Cancer|November 6, 2018
Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myelomaAjai Chari, Sagar Lonial, Tomer M Mark, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 28, 2020
Exploiting Protein Translation Dependence in Multiple Myeloma with Omacetaxine-Based TherapyZachary J Walker, Beau M Idler, Lorraine N Davis, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 13, 2017
A Phase I Trial of High-Dose Lenalidomide and Melphalan as Conditioning for Autologous Stem Cell Transplantation in Relapsed or Refractory Multiple MyelomaTomer M Mark, Danielle Guarneri, Peter Forsberg, et al.
Blood Advances|August 30, 2023
CD38 antibody re-treatment in daratumumab-refractory multiple myeloma after time on other therapiesOlivia Perez de Acha, Lauren Reiman, David S Jayabalan, et al.
American Journal of Hematology|August 23, 2021
Carfilzomib and dexamethasone induction with lenalidomide, clarithromycin and dexamethasone consolidation and lenalidomide maintenance for newly diagnosed multiple myelomaPeter A Forsberg, Adriana C Rossi, Angelique Boyer, et al.
British Journal of Haematology|February 8, 2021
Health-related quality of life maintained over time in patients with relapsed or refractory multiple myeloma treated with daratumumab in combination with bortezomib and dexamethasone: results from the phase III CASTOR trialVania Hungria, Meral Beksac, Katja C Weisel, et al.
American Journal of Hematology|February 12, 2019
Phase II study of carfilzomib and dexamethasone therapy for newly diagnosed multiple myelomaPeter A Forsberg, Adriana C Rossi, Angelique Boyer, et al.
Bone Marrow Transplantation|June 14, 2019
High-dose bendamustine and melphalan conditioning for autologous stem cell transplantation for patients with multiple myelomaAlexandra Gomez-Arteaga, Tomer M Mark, Danielle Guarneri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 30, 2013
Overcoming the response plateau in multiple myeloma: a novel bortezomib-based strategy for secondary induction and high-yield CD34+ stem cell mobilizationRuben Niesvizky, Tomer M Mark, Maureen Ward, et al.
The New England Journal of Medicine|August 25, 2016
Daratumumab, Bortezomib, and Dexamethasone for Multiple MyelomaAntonio Palumbo, Asher Chanan-Khan, Katja Weisel, et al.
Pageof 5